Drug intelligence / Profile preview

Amediplase

Development stage: Unknown
Lead developer: Menarini
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Amediplase is a recombinant chimeric protein, classified as a third-generation thrombolytic agent. It is composed of functional domains from both tissue plasminogen activator (t-PA) and pro-urokinase plasminogen activator (scu-PA), specifically the kringle 2 domain of alteplase and the protease domain of urokinase. Developed by Menarini, it is being investigated for the treatment of thrombosis and myocardial infarction. Its mechanism involves activating plasminogen to plasmin, which then degrades fibrin to dissolve blood clots. Studies suggest it may be a more potent thrombolytic agent than Tenecteplase and scu-PA at therapeutic concentrations, with moderate fibrin binding that does not hinder clot penetration.

Other names: K2 tu-PAK-2 tu-PAK 2 tu-PA

Targets

PLG (Plasminogen)

Beyond the preview

Go deeper on Amediplase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amediplase.

Explore the full profile